Skip to main content

Manuel Comabella Lopez

Dr. Manuel Comabella earned his medical degree at the University of Barcelona, completed his neurology residency at the Neurology Department of the Hospital Universitari Vall d’Hebron (HUVH), and earned his PhD at the Universitat Autònoma de Barcelona. Since 2004, Dr. Manuel Comabella is the Head of the Clinical Neuroimmunology laboratory at the Fundació Institut de Recerca del HUVH. Since June 2008 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology of the MS Centre of Catalonia (Cemcat), HUVH, Barcelona.

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Responsable Laboratori
Multiple Sclerosis Centre of Catalonia

Manuel Comabella Lopez

Institutions of which they are part

Main researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Responsable Laboratori
Multiple Sclerosis Centre of Catalonia

Dr. Manuel Comabella earned his medical degree at the University of Barcelona, completed his neurology residency at the Neurology Department of the Hospital Universitari Vall d’Hebron (HUVH), and earned his PhD at the Universitat Autònoma de Barcelona. Since 2004, Dr. Manuel Comabella is the Head of the Clinical Neuroimmunology laboratory at the Fundació Institut de Recerca del HUVH. Since June 2008 he works as a clinical neurologist at the Department of Neurology / Neuroimmunology of the MS Centre of Catalonia (Cemcat), HUVH, Barcelona.

From 1996 to 1998, Dr. Manuel Comabella was a Research Fellow in Neuroimmunology at the Center for Neurologic Diseases, Brigham and Women´s Hospital, in Boston. In 2010 was awarded with the Ayudas Merck Serono in the multiple sclerosis research area. In 2011 was awarded by the Spanish Society of Neurology (SEN) with the Biogen Idec Prize to the best publication on demyelinating disorders. In 2013 was awarded by the SEN with the Novartis Prize to the best oral communication and the best publication on demyelinating disorders. In 2014 received the Neurological Disorders Award, scientific modality, granted by the SEN. In 2016 was awarded with the Ayudas Merck Serono in the multiple sclerosis research area. From 2018 to 2020, Dr. Manuel Comabella was a collaborator of the Biomedicine area at the Division of Coordination, Evaluation and Scientific and Technical Follow-up of the State Research Agency, Ministry of Science, Innovation and Universities.

Dr. Manuel Comabella is member of the Editorial Board of Journal of Neuroimmunology and Multiple Sclerosis Journal, member of the Board of the ESNI (European School of Neuroimmunology), and member of the Strategic Group of the IMSGC (International Multiple Sclerosis Genetics Consortium). He is coauthor of 297 documents indexed in MedLine (Scopus: 12916 total citations, with h-index of 54). Dr. Manuel Comabella's research interest lies in the identification of biomarkers related with different aspects of multiple sclerosis and the development of new therapeutic strategies for the disease.

Research lines

Biomarkers of susceptibility, diagnosis and prognosis in MS (IV)

Study of humoral responses against Epstein-Barr virus as a long-term prognostic factor in patients with MS.


Characterization of the immunological profiles associated with the different MS phenotypes.


Study of extracellular vesicles derived from CNS cells as prognostic biomarkers in patients with MS.


IP: Manuel Comabella Lopez

Study of the pathogenesis of MS and search for new targets and/or therapeutic approaches (II)

Delve in the characterization of therapeutic targets identified by the group i.e. chitinase 3-like 1 and the NLRP3 inflammasome, for the development of new treatments in patients with MS.


Development of new humanized preclinical models of MS to investigate primary glial pathology, as well as the neuroprotective potential of new therapeutic agents: (i) generation of human glial chimeric mice with experimental autoimmune encephalomyelitis; (ii) transplantation of oligodendrocytes derived from MS patients into demyelinated human brain-slice cultures.

IP: Manuel Comabella Lopez

Projects

Beca VHIR PhD

IP: Manuel Comabella Lopez
Collaborators: Sira Rodrigo Bosch, Laia Perez Lasarte, Elisa Marín Ordovás, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 69188.74
Reference: VPHD/ELISA_M
Duration: 01/04/2023 - 31/03/2026

BEHIND-MS: The role of an Epstein-Barr virus infection in the pathogenesis of multiple sclerosis

IP: Manuel Comabella Lopez
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 248720
Reference: BEHIND-MS_HE-HLTH2023
Duration: 01/12/2023 - 30/11/2028

Red de investigación en inflammasoma y piroptosis en enfermedades crónicas y cáncer

IP: Manuel Comabella Lopez
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 0.01
Reference: RED2022-134511-T
Duration: 01/06/2023 - 31/05/2025

Ministerio de Ciencia

TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas

IP: Begoña Benito Villabriga
Collaborators: Carmen Escudero Iriarte, Ventura i Expósito, Laia, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Perez Dueñas, Belen, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, Ariadna Boloix Amenós, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Cazurro Gutierrez, Ana Laura, Gómez Andrés, David, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, Andres Miguez Gonzalez, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Bou Teen, Diana, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala
Funding agency: Instituto de Salud Carlos III
Funding: 2494527.53
Reference: FORT23/00034
Duration: 01/01/2024 - 31/12/2027

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Marc Simo Perdigo

Marc Simo Perdigo

Molecular Medical Imaging
Read more
Joaquim Sola  Santesmases

Joaquim Sola Santesmases

Zelador/a
General Services and Infrastructure
Manager
Read more
Tomas Pinós Figueras

Tomas Pinós Figueras

Senior researcher
Neuromuscular and Mitochondrial Pathology
Read more
Noelia Rodríguez Villatoro

Noelia Rodríguez Villatoro

Research technician
Stroke research
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.